Semaglutide cuts cardiovascular events 20% through unexplained pathways

The wire

1. 01In adults with overweight or obesity and established cardiovascular disease but without diabetes, semaglutide reduced major adverse cardiovascular events by 20%, researchers report.
2. 02Prescribers counselling cardiometabolic patients can point to benefit that appears to extend beyond weight loss and conventional risk-factor control.
3. 03The analysis cannot identify the additional biological pathways involved, and mediation findings of this kind remain inferential rather than causal.

From the source

Semaglutide cuts major heart events, but researchers still cannot fully explain why

In adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide reduced major adverse cardiovascular events by 20%, while changes in measured cardiovascular risk factors could not fully explain the benefit with certainty. The findings suggest that additional, as-yet unidentified biological pathways may contribute to semaglutide’s cardiovascular protection.